Top-tier fund specializing in early-stage life sciences and biotechnology investments. Managed over 15 deals primarily in North America and Europe, with notable exits including two successful IPOs. The investment style is characterized by a hands-on, operator-led approach, emphasizing collaboration with portfolio companies. Recognized for a rigorous selection process and deep industry expertise.